144 related articles for article (PubMed ID: 33041661)
1. Stigmasterol sensitizes endometrial cancer cells to chemotherapy by repressing Nrf2 signal pathway.
Liao H; Zhu D; Bai M; Chen H; Yan S; Yu J; Zhu H; Zheng W; Fan G
Cancer Cell Int; 2020; 20():480. PubMed ID: 33041661
[TBL] [Abstract][Full Text] [Related]
2. Metformin sensitizes endometrial cancer cells to chemotherapy through IDH1-induced Nrf2 expression via an epigenetic mechanism.
Bai M; Yang L; Liao H; Liang X; Xie B; Xiong J; Tao X; Chen X; Cheng Y; Chen X; Feng Y; Zhang Z; Zheng W
Oncogene; 2018 Oct; 37(42):5666-5681. PubMed ID: 29921847
[TBL] [Abstract][Full Text] [Related]
3. High levels of Nrf2 determine chemoresistance in type II endometrial cancer.
Jiang T; Chen N; Zhao F; Wang XJ; Kong B; Zheng W; Zhang DD
Cancer Res; 2010 Jul; 70(13):5486-96. PubMed ID: 20530669
[TBL] [Abstract][Full Text] [Related]
4. PGK1 facilities cisplatin chemoresistance by triggering HSP90/ERK pathway mediated DNA repair and methylation in endometrial endometrioid adenocarcinoma.
Zhou JW; Tang JJ; Sun W; Wang H
Mol Med; 2019 Mar; 25(1):11. PubMed ID: 30925862
[TBL] [Abstract][Full Text] [Related]
5. Brusatol enhances the efficacy of chemotherapy by inhibiting the Nrf2-mediated defense mechanism.
Ren D; Villeneuve NF; Jiang T; Wu T; Lau A; Toppin HA; Zhang DD
Proc Natl Acad Sci U S A; 2011 Jan; 108(4):1433-8. PubMed ID: 21205897
[TBL] [Abstract][Full Text] [Related]
6. LASS2 mediates Nrf2-driven progestin resistance in endometrial cancer.
Yang B; Hu M; Fu Y; Sun D; Zheng W; Liao H; Zhang Z; Chen X
Am J Transl Res; 2021; 13(3):1280-1289. PubMed ID: 33841656
[TBL] [Abstract][Full Text] [Related]
7. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-AKR1C1 pathway.
Wang Y; Wang Y; Zhang Z; Park JY; Guo D; Liao H; Yi X; Zheng Y; Zhang D; Chambers SK; Zheng W
Oncotarget; 2016 Mar; 7(9):10363-72. PubMed ID: 26824415
[TBL] [Abstract][Full Text] [Related]
8. Nrf2 induced cisplatin resistance in ovarian cancer by promoting CD99 expression.
Wu J; Zhang L; Li H; Wu S; Liu Z
Biochem Biophys Res Commun; 2019 Oct; 518(4):698-705. PubMed ID: 31472965
[TBL] [Abstract][Full Text] [Related]
9. Mechanism of progestin resistance in endometrial precancer/cancer through Nrf2-survivin pathway.
Fan R; Wang Y; Wang Y; Wei L; Zheng W
Am J Transl Res; 2017; 9(3):1483-1491. PubMed ID: 28386373
[TBL] [Abstract][Full Text] [Related]
10. Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.
Li C; Fan K; Qu Y; Zhai W; Huang A; Sun X; Xing S
J Cell Physiol; 2020 Apr; 235(4):3721-3730. PubMed ID: 31583720
[TBL] [Abstract][Full Text] [Related]
11. Aurora-A Induces Chemoresistance Through Activation of the AKT/mTOR Pathway in Endometrial Cancer.
Wu J; Cheng Z; Xu X; Fu J; Wang K; Liu T; Wu C; Kong X; Yang Q; Yan G; Zhou H
Front Oncol; 2019; 9():422. PubMed ID: 31192127
[TBL] [Abstract][Full Text] [Related]
12. The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer.
Hayden A; Douglas J; Sommerlad M; Andrews L; Gould K; Hussain S; Thomas GJ; Packham G; Crabb SJ
Urol Oncol; 2014 Aug; 32(6):806-14. PubMed ID: 24837013
[TBL] [Abstract][Full Text] [Related]
13. Nrf2 induces cisplatin resistance through activation of autophagy in ovarian carcinoma.
Bao LJ; Jaramillo MC; Zhang ZB; Zheng YX; Yao M; Zhang DD; Yi XF
Int J Clin Exp Pathol; 2014; 7(4):1502-13. PubMed ID: 24817946
[TBL] [Abstract][Full Text] [Related]
14. Cisplatin regulates cell autophagy in endometrial cancer cells via the PI3K/AKT/mTOR signalling pathway.
Lin Q; Wang Y; Chen D; Sheng X; Liu J; Xiong H
Oncol Lett; 2017 May; 13(5):3567-3571. PubMed ID: 28521459
[TBL] [Abstract][Full Text] [Related]
15. Fluorene-9-bisphenol inhibits epithelial-mesenchymal transition of human endometrial cancer Ishikawa cells by repressing TGF-β signaling pathway.
Wang L; Zhuang T; Li F; Wei W
Environ Sci Pollut Res Int; 2019 Sep; 26(26):27407-27413. PubMed ID: 31327139
[TBL] [Abstract][Full Text] [Related]
16. Metformin sensitizes endometrial cancer cells to chemotherapy by repressing glyoxalase I expression.
Dong L; Zhou Q; Zhang Z; Zhu Y; Duan T; Feng Y
J Obstet Gynaecol Res; 2012 Aug; 38(8):1077-85. PubMed ID: 22540333
[TBL] [Abstract][Full Text] [Related]
17. Post-translational down-regulation of Nrf2 and YAP proteins, by targeting deubiquitinases, reduces growth and chemoresistance in pancreatic cancer cells.
Grattarola M; Cucci MA; Roetto A; Dianzani C; Barrera G; Pizzimenti S
Free Radic Biol Med; 2021 Oct; 174():202-210. PubMed ID: 34364982
[TBL] [Abstract][Full Text] [Related]
18. Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression.
Jiang Y; Chen X; Wei Y; Feng Y; Zheng W; Zhang Z
Biomed Pharmacother; 2019 May; 113():108712. PubMed ID: 30849641
[TBL] [Abstract][Full Text] [Related]
19. ABCF2, an Nrf2 target gene, contributes to cisplatin resistance in ovarian cancer cells.
Bao L; Wu J; Dodson M; Rojo de la Vega EM; Ning Y; Zhang Z; Yao M; Zhang DD; Xu C; Yi X
Mol Carcinog; 2017 Jun; 56(6):1543-1553. PubMed ID: 28112439
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-423 promotes proliferation, migration and invasion and induces chemoresistance of endometrial cancer cells.
Li J; Sun H; Liu T; Kong J
Exp Ther Med; 2018 Nov; 16(5):4213-4224. PubMed ID: 30344696
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
